Combining resources of high quality samples and affinity reagents to advance our understanding of human biology has driven the development of novel assay procedures and technologies...Read more
Dr. Emma Lundberg has been identified as "Top 10 Under 40" by GEN. Together with nine other professionals in biopharma research/business Emma Lundberg has been recognized for her achievements...Read more
On May 9, Linn Fagerberg presented "Wellness profiling and the Human Protein Atlas" at a lunch seminar arranged by Science for Life Laboratories, during the three-day Keystone Symposia that took place in Stockholm.
Her presentation focused on personalized medicine, where she is involved in the Wellness profiling project...Read more
Testicular cancer is a rare type of cancer. Most testis cancers are curable, even at an advanced stage. The cancer can be divided into essentially two categories: Seminoma and Non-seminomatous germ cell tumors. Based on transcriptomics data and clinical metadata we have been able to determine 57 genes associated with either favorable or unfavorable prognosis in testis cancer...Read more
Head and neck cancer arises in the epithelium of the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. By using a systems level approach to analyze the head and neck cancer proteome based on clinical metadata and genome-wide transcriptomics data, 792 genes were found to be associated with prognostic outcome...Read more
December 8, 2018 - December 12, 2018
The Human Protein Atlas will be exhibiting at the 2018 ASCB EMBO meeting in San Diego. In booth number #624 you will meet the Cell Atlas team Emma Lundberg, Christian Gnann, Lovisa Åkesson and Peter Thul. They will also present four posters. Preliminary programme
March 28, 2019 - March 29, 2019
On March 29th, 2019, Mathias Uhlén will give a keynote on "The Human Protein Atlas - implications for human biology, drug development and precision medicine" at the International Rouen P2M Symposium on Precision Medicine "Pathways to Precision Medicine".